CSIMarket Company Name, Ticker, Suppliers, else..


Exelixis Inc   (NASDAQ: EXEL)
Other Ticker:  
 

Exelixis Inc

EXEL's Fundamental analysis



Looking into Exelixis Inc growth rates, revenue grew by 30.62 % in the first quarter of 2025 from the same quarter a year ago. Ranking at No. 1628

Biotechnology & Pharmaceuticals industry recorded growth of revenues by 11.96 %

Exelixis Inc 's net income grew by 321.91 % in first quarter of 2025 year on year, above company average,

• More on EXEL's Growth


Exelixis Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Exelixis Inc PEG ratio is at 0.08 Exelixis Inc realized cash reduction of $ -0.26 per share in trailing twelve-month period.
Company
18.81
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 5.21.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.2.


• More on EXEL's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 4,061,700
 Net Income/Employee (TTM) $ 2,617,719
 Receivable Turnover (TTM) 7.58
 Tangible Book Value (Per Share $) 7.17

Exelixis Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Exelixis Inc PEG ratio is at 0.08 Exelixis Inc realized cash outflow of $ -0.26per share in trailing twelve-month period.
Company
18.81
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 5.21.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.2.

Exelixis Inc Price to Book Ratio is at 5.62 lower than Industry Avg. of 1878.65. and higher than S&P 500 Avg. of 0.01

• More on EXEL's Valuation

•  Market Capitalization (Millions $) 11,985
•  Shares Outstanding (Millions) 288
•  Employees 566
•  Revenues (TTM) (Millions $) 2,299
•  Net Income (TTM) (Millions $) 1,482
•  Cash Flow (TTM) (Millions $) -76
•  Capital Exp. (TTM) (Millions $) -22
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 4,061,700
•  Net Income/Employee(TTM) $ 2,617,719
•  Receivable Turnover Ratio (TTM) 7.58
•  Tangible Book Value (Per Share $) 7.17

•  Market Capitalization (Millions $) 11,985
•  Shares Outstanding (Millions) 288
•  Employees 566
•  Revenues (TTM) (Millions $) 2,299
•  Net Income (TTM) (Millions $) 1,482
•  Cash Flow (TTM) (Millions $) -76
•  Capital Exp. (TTM) (Millions $) -22


    EXEL's Profitability Comparisons
Exelixis Inc achieved increase in profitability, due to cost control. Operating Margin grew in first quarter of 2025 to 33.64 % from 28.8 % in IV. Quarter.

Exelixis Inc net profit margin of 65.77 % is currently ranking no. 7 in Biotechnology & Pharmaceuticals industry, ranking no. 18 in Healthcare sector and number 94 in S&P 500.


Profitability by Segment
Reportable Segment 28.74 %
Total 65.77 %



  Ratio
•   Capital Ratio (MRQ) 3.5
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 0.34
•  Asset Turnover Ratio (TTM) 0.92
•  Inventory Turnover Ratio (TTM) 3.34



Exelixis Inc achieved increase in profitability, due to cost control. Operating Margin grew in first quarter of 2025 to 33.64 % from 28.8 % in IV. Quarter.

Exelixis Inc net profit margin of 65.77 % is currently ranking no. 7 in Biotechnology & Pharmaceuticals industry, ranking no. 18 in Healthcare sector and number 94 in S&P 500.

• More on EXEL's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com